Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis.
Anxiety is a common symptom in Idiopathic Pulmonary Fibrosis, with prevalence estimates as high as 60%. A US claims analysis reveals that 31% of patients with pulmonary fibrosis and 39% of patients with Idiopathic Pulmonary Fibrosis are prescribed medications for anxiety or depression.
Almee™ is intended to be used on top of standard of care for pulmonary fibrosis and is not intended to treat the physical aspects of pulmonary fibrosis. The therapy will be delivered in a sequence of interactive modules of neurobehavioral interventions, patient education, and skill- building, and consists of sound exercises, video exercises, and interactive exercises as part of the CBT toolbox. Cognitive behavioral therapy (CBT) is a well-established method to support patients who carry a high psychological burden caused by severe disease. A digital CBT is delivered via a software application on a patient’s mobile device, can be personalized and is accessible round-the-clock to meet the patient’s individual needs and schedule.
Read more about Almee here: https://www.almeetherapy.com/
The COMPANION pivotal investigation is being conducted in the US and aims to include patients with anxiety related to pulmonary fibrosis. It is a 9-week, randomized, controlled, fully virtual and decentralized clinical investigation to evaluate the impact of digital CBT on psychological symptom burden and quality of life in adults living with pulmonary fibrosis.
People who are interested may visit www.vicorecompanionstudy.com – the COMPANION investigation website – where people living with pulmonary fibrosis can answer a few questions to check eligibility.
Almee™ is developed in collaboration with Alex Therapeutics – a digital therapeutics (DTx) company partnering with pharmaceutical companies to create and license digital therapies.